Gene mutation defends against Alzheimer's disease

ArticleinNature 487(7406):153 · July 2012with5 Reads
DOI: 10.1038/487153a · Source: PubMed
Rare genetic variant suggests a cause and treatment for cognitive decline.
    • "Some of the antineurodegenerative drugs are enlisted below (Figs. 1 and 2). Among the above mentioned neurodegenerative diseases, AD is the most common pathological subtype of ND which currently affects more than 30 million people worldwide [5], causing a heavy personal loss on the patient and their family. "
    Dataset · Feb 2016 · Journal of Medicinal Chemistry
  • [Show abstract] [Hide abstract] ABSTRACT: Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, applying knowledge, and changing preferences. It involves memory, attention, executive functions, perception, language, and psychomotor functions. The term nootropics was coined in 1972 when memory enhancing properties of piracetam were observed in clinical trials. In the meantime, hundreds of drugs have been evaluated in clinical trials or in preclinical experiments. To classify the compounds, a concept is proposed assigning drugs to 19 categories according to their mechanism(s) of action, in particular drugs interacting with receptors, enzymes, ion channels, nerve growth factors, re-uptake transporters, antioxidants, metal chelators, and disease modifying drugs meaning small molecules, vaccines, and monoclonal antibodies interacting with amyloid-β and tau. For drugs whose mechanism of action is not known, they are either classified according to structure, e.g., peptides, or their origin, e.g., natural products. This review covers the evolution of research in this field over the last 25 years.
    Full-text · Article · Oct 2012
  • [Show abstract] [Hide abstract] ABSTRACT: Beta-secretase (BACE1), the enzyme responsible for the first and rate-limiting step in the production of amyloid-beta peptides, is an attractive target for the treatment of Alzheimer's disease. In this study, we report the application of the de novo fragment-based molecular design program SPROUT to the discovery of a series of non-peptide BACE1 inhibitors based upon a biphenylacetamide scaffold. The binding affinity of molecules based upon this designed molecular scaffold was increased following the synthesis of a library of optimized ligands whose structures were refined using the recently developed SPROUT-HitOpt software. Although a number of inhibitors were found to exhibit cellular toxicity, one compound in the series was found to have useful BACE1 inhibitory activity in a cellular assay with minimal cellular toxicity.
    Article · Feb 2013
Show more

Recommended publications

Discover more